India, September 18, 2026
Concept Medical is highlighting new subgroup findings from the SirPAD randomized clinical trial that will be presented during VIVA 2026, with a focus on patients with femoropopliteal peripheral artery disease (PAD) and intermittent claudication. The late-breaking analysis examines a clinically important group of patients with symptomatic lower-extremity arterial disease who underwent treatment with either the company’s MagicTouch sirolimus-coated balloon or an uncoated balloon. The findings are scheduled for presentation at VIVA 2026, taking place October 3–6, 2026, at Bellagio Las Vegas. The analysis focuses specifically on patients with femoropopliteal disease who did not have tissue loss, addressing treatment outcomes beyond simply preserving the limb and examining the potential importance of durable symptom relief following revascularization.
SirPAD Analysis Targets Femoropopliteal PAD
The SirPAD trial randomized 1,252 patients with symptomatic infrainguinal peripheral artery disease to undergo angioplasty using either the MagicTouch sirolimus-coated balloon or an uncoated balloon. The newly announced subgroup analysis includes 597 patients with femoropopliteal disease without tissue loss. This population is particularly relevant in peripheral vascular medicine because patients experiencing intermittent claudication can have substantial limitations in walking ability and daily activities even when they are not facing immediate limb-threatening ischemia. According to Concept Medical, the subgroup analysis is intended to provide additional insight into outcomes in this specific patient population and will be presented as part of the late-breaking clinical trial program at VIVA 2026, an international meeting focused on peripheral vascular disease and endovascular therapy.
The SirPAD program represents an investigator-initiated randomized controlled trial evaluating the role of a sirolimus-coated balloon in patients with femoropopliteal or below-the-knee arterial disease. The trial’s primary findings were recently published in the New England Journal of Medicine, according to Concept Medical. The company states that the trial demonstrated that treatment with the sirolimus-coated balloon was non-inferior and superior to uncoated balloon treatment for major adverse limb events (MALE). The newly selected subgroup presentation provides an opportunity to examine these findings more closely among patients with femoropopliteal disease and intermittent claudication.
MagicTouch Technology Supports Endovascular Treatment
Advertisement
The technology at the center of the study is MagicTouch PTA, a sirolimus-coated balloon catheter developed by Concept Medical for peripheral vascular interventions. Drug-coated balloon technologies are designed to deliver an antiproliferative drug directly to the treated arterial segment during angioplasty. In the SirPAD study, MagicTouch was evaluated against an uncoated balloon, allowing investigators to assess clinical outcomes associated with the use of the drug-coated technology in symptomatic peripheral artery disease. Concept Medical develops drug-delivery technologies for both coronary and peripheral vascular interventions, with MagicTouch PTA forming part of its peripheral intervention portfolio. For patients with femoropopliteal PAD and intermittent claudication, successful revascularization can have goals that extend beyond preventing major limb complications. Improvement in symptoms, walking capacity and functional status can also be important measures of treatment benefit. The subgroup analysis being presented at VIVA 2026 therefore adds clinical context to the broader SirPAD findings by concentrating on patients whose primary treatment objective may include durable symptom relief and improved functional outcomes. The presentation will be delivered by Prof. Dr. Stefano Barco, Co-Principal Investigator of the SirPAD trial, during the late-breaking clinical trial program.
VIVA 2026 Presentation Adds New Clinical Insight
The presentation of the SirPAD subgroup analysis at VIVA 2026 will provide additional clinical information on the performance of sirolimus-coated balloon angioplasty in a defined femoropopliteal PAD population. The findings are expected to contribute to ongoing discussion around endovascular therapy, drug-coated balloon technology and peripheral artery disease management. As the analysis represents a subgroup of the larger randomized trial, its findings should be interpreted within the context of the overall SirPAD study and the specific characteristics of the patients included in the analysis. The upcoming presentation further demonstrates the continued evaluation of drug-delivery technologies in peripheral vascular intervention and their potential role in treating symptomatic arterial disease.
Source: Telix Pharmaceuticals, ITM press release
